
Opinion|Videos|May 19, 2025
Key Differences Among ALK Inhibitors
Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.
Advertisement
Episodes in this series

ALK Inhibitor Comparison and CNS Penetration
Key Themes:
- Overview of currently available ALK inhibitors in the metastatic setting
- Comparative analysis of efficacy and durability of response
- Differences in CNS penetration among ALK inhibitors
Notable Insights:
- Dr Lovly provided a comprehensive overview of available ALK inhibitors and their comparative efficacy
Dr Dietrich highlighted clinically relevant differences in CNS penetration and their influence on therapy selection
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
2
New Biomarkers, Drug Targets Identified for Colorectal Cancer
3
First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC
4
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
5